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ABSTRACT
Objective: Laboratory tests including optical platelet
aggregometry (OPA), platelet function analyser (PFA-100),
and thromboxane B2 (TXB2) metabolite levels have been
used to define aspirin resistance. This study characterised
the prevalence of aspirin resistance in patients with
ischaemic heart disease (IHD) and investigated the
concordance and repeatability of these tests.
Design, setting and patients: Consecutive outpatients
with stable IHD were enrolled. They were commenced on
150 mg aspirin daily (day 0) and had platelet function
assessment (OPA and PFA-100) and quantitative analysis
of serum/urine TXB2 at day >7 and then at a second visit
approximately 2 weeks later.
Main outcome measures: We assessed the prevalence
of aspirin resistance by each method, concordance
between methods of measuring response to aspirin and
association between time points to assess the predict-
ability of response over time.
Results: 172 patients (62.7 (SD 8.7) years, 83.1% male)
were recruited. At visits 1 and 2, respectively, 1.7% and
4.7% were aspirin resistant by OPA, whereas 22.1% and
20.3% were aspirin resistant by PFA-100. There were
poor associations between PFA-100 and OPA, and
between TXB2 metabolites and platelet function tests.
OPA and PFA-100 results were poorly associated
between visits (k=0.16 and k=0.42, respectively) as
were TXB2 metabolites, suggesting that aspirin resistance
is not predictable over time.
Conclusions: The prevalence of aspirin resistance is
dependent on the method of testing. Response varies on
a temporal basis, indicating that testing on a single
occasion is inadequate to diagnose resistance or guide
therapy in a clinical setting.
Antiplatelet therapy, particularly aspirin, forms
the cornerstone of treatment for atherosclerotic
disease. The Antiplatelet Trialists’ Collaboration
reported a 25% reduction in vascular death,
myocardial infarction or stroke among high-risk
patients treated with aspirin.
1 Although there have
been significant reductions in the morbidity and
mortality associated with these disease processes,
there continues to be potential for improvement in
outcomes.
2 Atherosclerosis and thrombus forma-
tion are complex processes, and the absolute risk of
a recurrent event in patients with known disease
remains high at approximately 8–18% after 2
years.
3 Aspirin is classified as a ‘‘weak platelet
antagonist’’
4 whose effect on inhibition of platelet
function is not predictable. Studies have suggested
that the antiplatelet effects of aspirin may not be
equivalent in all,
5 leading to the development of
the concept of ‘‘aspirin resistance’’. There is no
agreed universal definition of aspirin resistance,
making comparison of studies within this field
difficult. One use of the term has been to describe
patients who continue to experience vascular
complications despite aspirin therapy as having
‘‘clinical aspirin resistance’’,
6 although other inves-
tigators thought this would be better known as
‘‘treatment failure’’.
7 Other definitions of aspirin
resistance relate to its inability to produce an
expected effect on one or more tests of platelet
function or on the inhibition of biosynthesis of
thromboxane metabolites. These various assess-
ments all attempt to define ‘‘biochemical aspirin
resistance’’; however, the individual defining para-
meters of each test are not universally agreed. The
historical gold standard for assessment of platelet
function in acquired platelet function disorders,
including following aspirin ingestion, is optical
platelet aggregometry (OPA).
8
The exact prevalence of aspirin resistance or
non-response is uncertain owing to the lack of a
single, validated method of measurement, leading
to a wide range of population estimates from 5.5%
to 60%. Given the prevalence of atherosclerotic
disease, the potential impact of aspirin resistance
on all its clinical consequences is large. Identifying
aspirin non-responders and improving their plate-
let function inhibition by various methods could
have a very significant clinical impact.
3
Our study was designed to characterise the
prevalence of aspirin resistance by four different
methods (the gold standard optical aggregometry,
PFA-100 analyser testing, and both serum and
urine thromboxane levels) simultaneously in a
cohort of patients with stable coronary artery
disease and to assess relations between tests. We
also sought to assess the reproducibility of these
methods for detection of aspirin resistance by
repeating the tests on two separate occasions.
METHODS
Patients
In all, 175 patients with stable ischaemic heart
disease (IHD) were recruited from October 2004 to
June 2006. Three patients failed to return for repeat
testing, so results are presented for a total of 172
patients. Stable disease was defined as a confirmed
history of a myocardial infarction (MI), percuta-
neous coronary interventions (PCI) or coronary
artery bypass graft (CABG) at least 3 months
before enrolment or a history of angiographically
proved coronary artery stenosis of >50% stenosis
in one or more coronary arteries. Exclusion criteria
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event within 3 months of enrolment; ingestion of other
antiplatelet agents or non-steroidal anti-inflammatory drugs
(NSAIDs) (including cyclo-oxygenase-2 (COX-2) selective anti-
inflammatory drugs) within 2 weeks of enrolment; a history of
major surgery within 1 week of enrolment; previous significant
bleeding; known significant malignant disease or bleeding
diathesis; platelet count (150610
9/l or haemoglobin count of
(8 g/dl. This study complies with the Declaration of Helsinki
and was approved by the Queen’s University of Belfast research
ethics committee. All patients gave written informed consent.
Sampling
To maximise uniformity of pharmacokinetics, all patients were
prescribed 150 mg of dispersible aspirin daily. Patients attended
for tests on two occasions. The first visit took place >7 days
following change in aspirin dosage and the second visit occurred
approximately 14 days later. Patients continued the same dose
and formulation of aspirin between visits. Compliance was
assessed by interview at each visit and by telephone between
visits. Venesection was performed through a 21-gauge needle
and approximately 40 ml of whole blood was collected. All
blood samples were processed within 2 hours of collection. A
subgroup of patients provided an early morning urine sample
taken on the day of assessment. Samples for serum thrombox-
ane B2 (TXB2) were drawn at the same time as the samples for
platelet function testing so that levels of the metabolites could




A volume of 20 ml of whole blood was spun at 1000 rpm for
10 minutes to produce platelet-rich plasma (PRP), corrected to a
platelet count of approximately 250610
9/l using platelet-poor
plasma (PPP) as a diluent. PPP was obtained by spinning the
remaining cellular suspension following removal of PRP at
3000 rpm for 10 minutes. Aggregation was measured using a
Platelet Aggregation Profiler (PAP, BioData Corporation,
Horsham, USA) and was recorded as the maximal percentage
change in light transmittance from baseline, through corrected
PRP, following the addition of various reagents, using PPP as a
reference. Aggregometry was measured following the addition
of 25 ml of 0.5 mg/ml arachidonic acid (AA), or 25 mlo f1 0mM/ml
adenosine diphosphate (ADP). Subjects defined as ‘‘aspirin
resistant’’ had residual aggregation of >20% following addition
of AA and >70% following addition of ADP. These parameters
have beenusedby previousinvestigatorsand have beenassociated
with increased risk of adverse events.
8–10 The coefficients of
variation for AA and ADP aggregation were 31.2% (at a mean of
62 units) and 6.4% (at a mean of 87 units), respectively.
Platelet function analyser
The platelet function analyser (PFA-100, Dade Behring,
Marburg, Germany) system provides a quantitative measure
of primary, platelet-related haemostasis, by simulating in vitro
an artificial vessel wall under shear stress. Whole blood was
transferred to the standard cartridges and the time taken to
occlude the aperture and prevent blood flow through the
membrane coated with collagen and epinephrine (adrenaline)
(CEPI) recorded. Subjects with a CEPI (196 seconds despite the
ingestion of aspirin were defined as ‘‘aspirin non-responders’’.
This definition has been used by previous investigators and has
been associated with increased risk of adverse events.
8–10 The
coefficient of variation for PFA-100 was 17.9% (at a mean of 182
units).
Serum thromboxane B2 and urine 11-dehydro-thromboxane B2
measurement
Thromboxane B2 metabolites in both serum and urine were
measured using enzyme immunoassay kits (Cayman Chemicals,
MI, USA). There are no validated levels agreed within the
literature above which ‘‘aspirin resistance’’ can be reliably
diagnosed; therefore, these measurements were treated as
continuous variables in the statistical analysis. Thromboxane
metabolites were not normally distributed; hence patients were
divided into four equal-sized groups using quartiles of the
distribution. The coefficients of variation for serum TXB2 and
urine TXB2 assays were 9.0% (at a mean of 254 units) and 8.6%
(at a mean of 134 units), respectively.







Age (years) 62.7 (8.7) 61.9 (8.6) 66.6 (8.2) p=0.006
BMI (kg/m
2) 30.0 (4.3) 30.0 (4.2) 29.9 (5.2) p=0.915
History of smoking* 68.6% 66.2% 80.0% p=0.139
History of hypertension{ 49.1% 46.9% 60.0% p=0.191
History of diabetes{ 21.1% 22.8% 13.3% p=0.250
Hypercholesterolaemia" 76.0% 72.4% 93.3% P=0.015
Family history of IHD1 52.0% 51.7% 53.3% p=0.872
On b-blocker therapy 88.6% 87.6% 93.3% p=0.368
On ACE inhibitor therapy 78.9% 80.7% 70.0% p=0.192
On statin therapy 96.0% 95.9% 96.7% p=0.838
*History of smoking, smoking within 5 years of >20 pack years. {History of hypertension as per patient records. {History of
diabetes as per patient records. "Hypercholesterolaemia, previous total cholesterol >5.0 mmol/l. 1Family history of IHD, first
degree relative with confirmed IHD at (60 years.
ACE, angiotensin-converting enzyme; BMI, body mass index; IHD, ischaemic heart disease.








AA >20% 3 (1.7) 8 (4.7) 0.16
PFA-100 38 (22.1) 35 (20.3) 0.42
AA, arachidonic acid; PFA-100, platelet function analyser.
Secondary prevention of coronary disease
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Categorical variables are displayed as absolute counts and
percentages. In the analysis of associations between alternative
measures of resistance, 2-by-2 tables of counts were constructed
and the x
2 test performed. Thromboxane metabolites were
compared between aspirin-resistant and aspirin-sensitive
patients using the Mann-Whitney U test. To assess for a
relation between serum and urine thromboxane metabolites,
results were log transformed and scatterplots constructed.
Spearman’s correlation coefficient was used to assess for an
association. To assess repeatability between visits, 2-by-2 tables
of counts were constructed and the coefficient of agreement,
kappa (k), calculated.
11 For thromboxane metabolites, scatter-
plots of log-transformed data were constructed for visit 1
compared to visit 2 and intraclass correlation coefficients (ICC)
calculated to assess variation between time points.
12 All
statistics were performed using SPSS for Windows Version 11.
Significance was set at the 5% level.
RESULTS
The cohort of 172 patients who completed the study had a
mean age of 62.7 (SD 8.7) years and 143 (83.1%) were male.
Patient characteristics are shown in table 1. Using the gold
standard method of assessment, optical platelet aggregometry
(OPA), the prevalence of aspirin resistance within the cohort
was 1.7% and 4.7% at visits 1 and 2, respectively. By PFA-100 38
patients (22.1%) and 35 patients (20.3%) were aspirin non-
responders at visits 1 and 2, respectively (table 2).
Median serum TXB2 was 90.4 pg/ml (interquartile (IQ) range
43.2–230.2 pg/ml) at visit 1 and 112.0 pg/ml (IQ range 46.5–
236.7 pg/ml) at visit 2. Urine samples were collected in a subset
of patients (n=80). Urine 11-dehydro TXB2 levels were
395.3 pg/ml (IQ range 232.2–645.5 pg/ml) and 388.8 pg/ml
(IQ range 248.5–562.6 pg/ml) at each visit, respectively. There
were no significant differences in levels between visits
(Wilcoxon signed-rank test p=0.84 and p=0.75 for serum
and urine, respectively). None of the recorded patient char-
acteristics was independently associated with aspirin resistance
by any method but statistical analysis lacked power owing to
the small number of patients found to be resistant by the gold
standard measurement of OPA.
Association between measures of resistance
The PFA-100 measurement of aspirin ‘‘non-response’’ was
poorly associated with aspirin resistance by OPA. The assess-
ment was limited, however, by the small numbers of patients
found to be resistant by the gold standard method. There were
no significant associations between the two tests, with the
coefficients of agreement k=0.02 and 0.22 at visits 1 and 2,
respectively (tables 3 and 4). When serum TXB2 metabolite
levels were compared to the gold standard method of measuring
resistance, it was found that they too were poorly associated
(table 5). Receiver operating characteristic (ROC) curve analyses
showed that it was not possible to use a serum TXB2 cut-off
point to predict aspirin resistance by OPA (area under the curve
(AUC)=0.50 and 0.46 at visits 1 and 2, respectively).
Significant association between PFA-100 and serum TXB2 level
was observed only at the second visit (table 4). At this visit,
aspirin non-responders had a significantly higher level of serum
TXB2 but there was considerable overlap of values for
responders and non-responders. Again, ROC curve analyses
indicated that it was not possible to select a cut-off point in
serum TXB2 level to predict aspirin non-response by PFA-100
(AUC=0.56 and 0.37 at visits 1 and 2, respectively). There were
also no significant associations observed between serum and
urine thromboxane metabolites at either visit (data not
presented). Urine 11-dehydro TXB2 levels were not assessed
for an association with aspirin resistance by the gold standard
because of small numbers available for the analyses. The urine
metabolite was assessed in a subset for an association with
aspirin non-response by PFA-100 and this did not reach
statistical significance at either visit. This indicated that it
was inappropriate to select a urinary level of 11-dehydro TXB2,
beyond which aspirin non-response could reliably be predicted
by PFA-100 (Mann Whitney U test p=0.99 and 0.36 at visits 1
and 2, respectively).
Associations between visits
Aspirin resistance by the gold standard method of optical
platelet aggregometry demonstrated poor association between
visits. The coefficient of agreement k between visits was 0.16
indicating a slight agreement only (table 2). This indicates that
aspirin resistance at visit 1 could not reliably predict resistance
at visit 2. There was a small improvement in the association
between the PFA-100 results between visits, with a coefficient
of agreement k=0.42, indicating a moderate level of agreement.
In the assessment of the repeatability of serum and urine
TXB2 metabolites, there were no statistically significant
associations between the levels of either metabolite between
visits. The intraclass correlation coefficient for the serum
metabolite was 0.49 and for urine 0.59, indicating TXB2
metabolites varied significantly within patients between visits
1 and 2. This suggests that measurement of either metabolite at
visit 1 is unable to accurately predict the level at visit 2.
DISCUSSION
Prevalence of aspirin resistance
In our study the prevalence of aspirin resistance by the historical
gold standard of OPA was 1.7% and 4.7% at visits 1 and 2,
respectively, somewhat lower than that found in other studies.
A recent review of the prevalence of aspirin resistance found a
mean pooled prevalence (as defined by AA-induced aggregation)
of 6% (95% CI 1% to 12%) and was dependent on the dose of
agonist used.
13 In 2001, Gum et al assessed patients with stable
coronary artery disease and found aspirin resistance by OPA in
5.5%.
8 In that study, the use of enteric-coated aspirin may
account for the difference in prevalence, as the formulation of
aspirin ingested affects the amount of aspirin absorbed and,
consequently, the degree of platelet function inhibition.
14 The
PFA-100 has been more widely investigated as a method for
assessment of platelet response to aspirin because the gold
standard method of platelet aggregometry is not suitable for use
in the acute setting. The review quoted a mean pooled
prevalence of aspirin non-response by PFA-100 of 28.1% (95%
CI 22.2% to 33.9%),
13 with other study results ranging from
Table 3 Association between aspirin resistance by arachidonic acid





sensitive (%) Total (%)
PFA-100 resistant 1 (33.3) 37 (21.9) 38 (22.1)
PFA-100 sensitive 2 (66.7) 132 (78.1) 134 (77.9)
Total 3 (100.0) 169 (100.0) 172 (100.0)
AA, arachidonic acid; PFA-100, platelet function analyser-100.
Coefficient of agreement between methods, k=0.02.
Secondary prevention of coronary disease
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with varying doses of aspirin (100–300 mg/day).
15 16 The lower
prevalence in our study may be attributed to improved patient
compliance and the use of 150 mg of dispersible aspirin.
Associations between measures of resistance
The association between platelet function studies is of great
importance as prediction of response to aspirin therapy has
gained popularity and many clinicians now think this state of
abnormal response to aspirin therapy warrants specific therapy.
It has been suggested that patients with ACS have higher
residual levels of platelet reactivity and that they may benefit
‘‘from an alternative or intensified antiplatelet regimen’’,
17 but
no single test encompasses all of the distinct and integrated
biological events of platelet biology and function.
18 To date, the
only studies to correlate clinical outcome with measures of
aspirin resistance have used AA-induced aggregation,
9 the rapid
platelet function analyser
19 or thromboxane B2 metabolites in
urine
20 as their measure of aspirin resistance. In our study, the
PFA-100 poorly predicted aspirin resistance by AA-induced
OPA, consistent with other studies performed previously.
82 1If
we assumed that OPA was the gold standard of measuring
aspirin resistance, then in this study the PFA-100 had a
sensitivity of 67% at visit 1 and 25% at visit 2, with poor
specificities of 22% and 18% at each visit, respectively, but the
power of this is limited by the small numbers of resistant
patients by the ‘‘gold standard’’. Recently, Faraday et al
examined the concordance of platelet aggregation, PFA-100,
both urinary and serum TXB2, fibrinogen, von Willebrand factor
and C-reactive protein levels in healthy volunteers.
22 Of the five
patients resistant by aggregometry criteria, four were also
resistant by PFA-100. Our study resulted in no significant
association between aggregation and PFA-100 at visit 1, but a
weak association at visit 2; however, confidence intervals are
wide as the study was limited by the low prevalence of aspirin
resistance by the gold standard method and it cannot safely be
concluded that any association exists between the two tests.
Marcucci et al performed PFA-100 assessment in patients
undergoing primary percutaneous intervention for acute MI.
PFA-100 non-response was a significant independent predictor
of the composite endpoint of cardiac death, new MI or target
vessel revascularisation,
23 but assessments were in the acute
setting while patients were on other antiplatelet medications;
therefore, the association between the PFA-100 results and
clinical outcome remains unproved. Some authors suggest that
the correct definition of aspirin resistance is a failure to
adequately inhibit platelet TXA2 production, reflecting the
mode of action of the drug.
9 TXA2 is an unstable metabolite;
thus, its production is determined by measurement of its stable
metabolites in serum and urine. Eikelboom et al found that
increasing quartile of urinary TXB2 was associated with a
composite endpoint of cardiovascular death, MI or stroke. This
study had many potential confounding variables, such as
compliance and measurement in the acute setting, so that
elevated TXB2 levels may have been caused by a recent event.
24
Rouvier et al correctly suggested that even with significant
depression of TXB2 metabolites, a normal aggregation pattern
can be observed
25 and the Eikelboom study should not be
interpreted as evidence to use therapy targeted at lowering
TXB2 metabolite levels to reduce future clinical events.
Our study found that serum TXB2 metabolite levels were
poorly associated with the gold standard method of measuring
resistance, which would be in keeping with results in normal
volunteers.
22 Recently authors have dichotomised the contin-
uous variable TXB2 by defining cut-off points for aspirin
resistance.
26 When these parameters were applied to our
population, there remained no significant association between
serum TXB2 levels and either aggregation or PFA-100 resistance
(data not presented).
Associations between visits
The response to aspirin is thought to vary on a temporal basis. A
few studies have assessed platelet aggregation in patients
undergoing prolonged aspirin treatment, the results of which
are conflicting.
27–29 Our study is the first one to assess the effect
of aspirin on multiple platelet function assessments on a
Table 4 Association between aspirin resistance by arachidonic acid





sensitive (%) Total (%)
PFA-100 resistant 6 (75.0) 29 (17.7) 35 (20.3)
PFA-100 sensitive 2 (25.0) 135 (82.3) 137 (79.7)
Total 8 (100.0) 164 (100.0) 172 (100.0)
AA, arachidonic acid; PFA-100, platelet function analyser-100.
Coefficient of agreement between methods, k=0.22.
Table 5 Comparison of serum thromboxane B2 levels with resistance by OPA and non-response by PFA-100
resistance cohort (n=172)
Resistant by AA aggregation Sensitive by AA aggregation Significance
TXB2 at visit 1 146.8 pg/ml 89.6 pg/ml p=0.99
(11.0–334.8) (43.5–230.0)
n=3 n=169
TXB2 at visit 2 120.9 pg/ml 111.3 pg/ml p=0.69
(28.3–219.3) (46.6–252.1)
n=8 n=164
Non-response by PFA-100 Sensitive by PFA-100 Significance
TXB2 at visit 1 84.2 pg/ml 92.8 pg/ml p=0.30
(37.3–175.6) (43.5–231.3)
n=38 n=134
TXB2 at visit 2 194.6 pg/ml 92.9 pg/ml p=0.02
(46.6–544.6) (46.4–201.1)
n=35 n=137
Results displayed as medians and interquartile ranges.
AA, arachidonic acid; PFA-100, platelet function analyser-100; TXB2, thromboxane B2.
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between visits so that the only variable to be assessed was
change in response with time. Three patients at visit 1 were
found to be resistant by aggregation and only one of these
remained so at the second visit. The numbers involved lack
power to allow detailed conclusions to be drawn and further
studies are required to assess the relation of aspirin resistance by
platelet function testing with time.
A recent meta-analysis reported that 28% of patients were
aspirin resistant and were at increased risk of cardiovascular
death, acute coronary syndrome, failure of vascular intervention
or a new cerebrovascular event compared to sensitive patients.
30
This suggests that measurement of platelet response to aspirin
can predict outcome and should be used to guide therapy. This
area, however, remains controversial and has not been
conclusively proved to date. Our study found that aspirin
resistance measurement varies on a temporal basis, making a
single measurement at a single time point inadequate to assess
an individual’s platelet response to aspirin.
Study limitations
This study does not investigate the association between platelet
function response and outcome. The correlation of laboratory-
defined aspirin resistance with clinical adverse events remains
an important issue. We are undertaking ongoing clinical follow-
up of this cohort of patients. However, to date, the small
number of clinical adverse events precludes current statistical
analysis of the data. Statistical analysis for associations between
platelet function tests and urine TXB2 levels was also limited in
this study as urine was collected in a subgroup of patients only.
Finally, there are no previously published data on coefficients of
variation of the assays used in this study. Some of the
coefficients of variation found were higher than would be ideal
but this was mainly because of the low level of platelet
aggregation found with the AA at OPA in patients treated with
aspirin.
CONCLUSIONS
The phenomenon of aspirin resistance remains a hotly debated
topic as there is no universally accepted definition of what
aspirin resistance is. This study was undertaken as an
independent assessment of the prevalence of aspirin resistance
in a cohort of patients with stable IHD in Northern Ireland. We
have shown that the prevalence of aspirin resistance is
extremely dependent on the measure of platelet function used
to assess response and that different methods produce widely
varying prevalence rates for resistance that do not correlate well
with each other. The prevalence varies on a temporal basis
because, at best, only a very weak association was found
between results at visits 1 and 2. This suggests that measure-
ment of aspirin resistance at a single time point may not predict
the response to therapy over time and, therefore, currently
limits the applicability of aspirin resistance testing to guide
antiplatelet therapy in a clinical setting.
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